TAVI more prominently featured in latest guideline

When intervention is considered, patients should be evaluated by a Heart Team (Class 1C-EO)

Engagement between the Heart Team and the primary clinical cardiologist is of critical importance

Recommendations for intervention now focus on age and shared decision-making

For symptomatic SAS patients 65 to 80 years old, TAVI should be considered, based on shared decision-making

Indications for TAVI are expanding as a result of multiple randomised trials, including the latest PARTNER trials, which are reflected in these recommendations

Patients should be evaluated regularly with examinations and transthoracic echocardiogram (TTE) every year at a minimum

TAVI is now recommended for a large number of patients based on expanded indications.

2020 ACC/AHA guideline on intervention recommendations by age

For symptomatic patients with severe AS and no anatomic contraindication to transfemoral TAVI

Key factors for considering valve intervention for Symptomatic SAS patients have changed

References:   1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020. Epublished DOI: 10.1016/j.jacc.2020.11.018.